Skip to main content
Clinical Trials/NCT03827993
NCT03827993
Terminated
Not Applicable

Improving Sexual Health in Gynecologic Cancer Patients

Case Comprehensive Cancer Center1 site in 1 country2 target enrollmentJuly 22, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gynecologic Cancer
Sponsor
Case Comprehensive Cancer Center
Enrollment
2
Locations
1
Primary Endpoint
Change in sexual dysfunction as measured by FSFI
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

This study seeks to find out if an early intervention of providing directed sexual health education and treatment for gynecologic cancer patients will improve patient outcomes as compared to routine clinic visits.

Detailed Description

Participants will be randomly placed to one of two groups. This random placement allows our research study to be more significant when the study team checks the results. In one group, the "control" group, participants will attend their usual clinic visits with their provider every 3 months for a year. At each clinic visit participants will be asked to fill out 3 short surveys (each takes less than 3 minutes). Participants will have a gynecologic exam like they routinely would for cancer surveillance, and confidential notes will be made regarding their exam to assess for improvement or worsening over time. In the other group, the "intervention" group, participants will attend one focused Sexual Health Clinic visit, where a provider specialized in sexual health for cancer patients will review a focused history and physical, and will provide education, as well as recommend any helpful treatments. This provider may or may not recommend follow up with her again after this initial visit. Participants will otherwise continue the usual every 3 month clinic visits with their Gynecologic Oncologist for a year. At each clinic visit participants will be asked to fill out 3 short surveys (each takes less than 3 minutes). Participants will have a gynecologic exam like they routinely would for cancer surveillance, and confidential notes will be made regarding their exam to assess for improvement or worsening over time. Participants will not need any additional blood draws or procedures. During their gynecologic exam, a swab will be collected to test participants vaginal pH - a test to see the health of their vaginal flora. In brief, participants will have their usual 4 clinic visits: one at 3 months, 6 months, 9 months, and 12 months. At each visit, participants will fill out 3 surveys and have a gynecologic exam performed as they usually would, but with a vaginal swab for vaginal pH. This swab will be assessed in the clinic by their provider as the swab will change colors to show pH at the time of exam. This result will be noted in the participants' chart and the swab will be discarded.

Registry
clinicaltrials.gov
Start Date
July 22, 2019
End Date
June 15, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Able to consent
  • Screening positive for sexual health dysfunction as per baseline FSFI
  • Diagnosed with any gynecologic malignancy
  • It is acceptable to have received treatment prior to or during enrollment, including prior surgery, chemotherapy, radiation, hormonal therapy, or clinical trial.

Exclusion Criteria

  • Unable to speak English
  • Patients unable to consent

Outcomes

Primary Outcomes

Change in sexual dysfunction as measured by FSFI

Time Frame: At 3, 6, 9, and 12 months from start of treatment

Change in sexual function as measured by FSFI, a 19-question, standardized scale of female sexual function, validated in cancer survivors as compared to start of study.

Secondary Outcomes

  • Change in sexual distress as measured by FSDS(At 3, 6, 9, and 12 months from start of treatment)
  • Change in psychologic distress as measured by Kessler K10 Scale(At 3, 6, 9, and 12 months from start of treatment)
  • Change in clinical assessment of vaginal symptoms as measured by VAS(At 3, 6, 9, and 12 months from start of treatment)
  • Change in clinical assessment of vulvar symptoms as measured by VuAS(At 3, 6, 9, and 12 months from start of treatment)

Study Sites (1)

Loading locations...

Similar Trials